Untreatable Fits of Hyperventilation/Apnea in Pitt-Hopkins Syndrome

Antonio Martínez Monseny¹, María Pilar Póo² and Mercedes Serrano¹,²,³*

¹Genetic Medicine and Rare Diseases Pediatric Institute (IPER), Hospital Sant Joan de Déu, Barcelona, Spain
²Neuropediatric Department, Hospital Sant Joan de Déu, Barcelona, Spain
³U-703 Centre for Biomedical Research on Rare Diseases (CIBER-ER), Instituto de Salud Carlos III, Barcelona, Spain.

Submission: July 01, 2017; Published: July 17, 2017

*Corresponding author: Mercedes Serrano, Neuropediatric Department & Genetic Medicine, U-703 Centre for Biomedical Research on Rare Diseases (CIBER-ER), Instituto de Salud Carlos III, Passeig Sant Joan de Déu, 2, 08950 Esplugues, Barcelona, Spain, Tel: 34-93-253-2100; Fax: 34-93-280-3626; Email: mserrano@sjdhospitalbarcelona.org

Keywords:Breath-holding spells; Apnea episodes; Pitt hopkins syndrome

Introduction

Pitt-Hopkins syndrome (PTHS) (MIM#610954, ORPHA2896) is a rare autosomal dominant condition due to TCF4 gene mutation or deletion. PTHS is characterized by distinctive facial features, developmental delay, moderate-to-severe intellectual disability, epilepsy, constipation, and stereotypic movements [1,2]. Peculiarly, episodic hyperventilation and/or breath-holding while awake is presented by more than 50% of patients and less than half of them experience a spontaneous disappearance of these spells without treatment [3].

The underlying mechanism for these fits of hyperventilation/apnea is not well understood and no clinical recommendations for their treatment have been published, despite two reports describing an amelioration of hyperventilation/breath-holding episodes with Acetazolamide [4,5]. These episodes can appear in a variable range of age and have been also reported in Rett syndrome, and are sporadically present in other Neurodevelopmental diseases (personal observation). However, this breathing disturbance and especially breath-holding episodes lead to a disruption in patients’ normal activity, causing a discontinuation in their learning and their daily activities [5]. Furthermore, these episodes of apnea may cause cyanosis due to lower oxygen transportation, probably leading to right heart dysfunction in the long term.

Although there is no literature regarding the pathophysiology of these events in patients with PTHS, there is some information on Rett syndrome. Hagebeuk EE et al. [6] identified three groups of day time respiratory disturbances in these patients and observed hyperventilation could be followed by apnea, but apnea can also appear without hyperventilation. Although these breathing events might be influenced by behavioral issues, it doesn’t seem compatible with breath holding as an only explanation of the phenomena. Clinical studies in classic Rett syndrome have shown dysphasia and cardio respiratory irregularities during the day and night, also suggesting brainstem dysfunction as a possible pathogenic mechanism behind the breath disturbances. Thus, brainstem serotoninergic neurons are known to play an important role in the arrangement of breathing rhythm and pattern, and one patient with Rett syndrome showing good response to fluoxetine and buspirone has been reported [7].

Case Report

We describe an 11-year-old girl affected by PTHS (due to a missense mutation in TCF4 gene: c.1733G>A, p.Arg578His) that developed breathing disturbances beginning at the age of eight. The hyperventilation/breath-holding episodes appeared only when she was awake. The apnea episodes last 20 to 30 seconds with oxygen decreases up to 60% registered through pulse oximeter and a holter monitor, that registered up to more than 100 hyperventilation/breath-holding episodes per hour with mild bradycardia, and only during wakefulness. As co-morbidities she suffered partial complex seizures from the age of 6 and now follows antiepileptic therapy (carbamazepine 800mg/ day). The patient underwent three cranial magnetic resonances at different ages, showing normal findings (including posterior fossa structures).
To start with therapies, as it has been described as improving the apnea episodes associated with Rett syndrome, topiramate (150mg/day, two daily doses) was initiated, without clinical response after one month. Topiramate was interrupted and, at that time, following the only two reports found on this medical problem [4,5], she underwent Acetazolamide treatment (250mg/day, two daily doses). Acetazolamide was well tolerated with no relevant side effects. During the first week there was transient amelioration that disappeared soon after. Acetazolamide was stopped after 2 months of treatment. Then, we began different therapeutic assays working on different hypothetical bases to treat these spells: aripiprazol (initially 1mg/day and titration up to 4mg/day), clonidine (up to 40 micrograms in two daily doses), methylphenidate (20mg/day), and guanfacine (up to 2mg/day). All of these drugs were well tolerated and maintained at least 3 weeks but all of them resulted unsuccessful.

At that point in time, we again tried Acetazolamide, but using higher doses (500mg/day, two daily doses) with good tolerance, but without maintained clinical response. At some point in time the family reported an interesting observation: when the girl suffers a cough, hyperventilation/apnea episodes improved. An interview revealed that they usually gave her a cough syrup based on a combination of codeine and a phenothiazine called promethazine, an antihistamine with sedative properties. Following this clue, she underwent separated treatments with both drugs. Carbocisteine was used up to 750mg every 8 hours during three weeks without positive effect. The combination of carbocisteine and promethazine was also useless (up to 60mg of promethazine every 12 hours).

After the withdrawal of this last therapy, the patient underwent an upper respiratory infection without fever. Following our recommendation, parents did not give her any cough-syrup and, surprisingly, hyperventilation/breath-holding episodes also improved during this infection.

At the present time she is beginning treatment with sertraline, a drug which is increasing used for anxiety in genetic episodes also improved during this infection.